An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors

被引：8
|
作者：
Rodon, J. [1 ]
Li, J. [2 ]
Xue, J. [2 ]
Diao, Y. [3 ]
Xu, Y. [3 ]
Liu, G. [3 ]
Rao, C. [3 ]
Fan, B. [3 ]
Cheng, Y. [3 ]
Wang, J. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Early Drug Dev, Houston, TX 77030 USA
[2] Shanghai East Hosp, Oncol Dept, Shanghai, Peoples R China
[3] Sichuan Kelun Biotech Biopharmaceut Co Ltd, Clin Res Ctr, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
514O
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [41] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
    Ben George
    Richards, Donald A.
    Edenfield, William Jeffory
    Warner, Steven L.
    Mouritsen, Lars
    Bishop, Reyna
    Anthony, Stephen Patrick
    Bearss, David
    Vogelzang, Nicholas J.
    Whatcott, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Grivas, Petros
    Vogelzang, Nicholas J.
    Alva, Ajjai Shivaram
    Feyerabend, Susan
    Loriot, Yohann
    Necchi, Andrea
    Gupta, Sumati
    Josephs, Debra Hannah
    Rodriguez-Vida, Alejo
    Srinivas, Sandy
    Zakharia, Yousef
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew
    Nepert, Dale L.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [43] A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer
    Haddad, R. I.
    Krebs, A. D.
    Vasselli, J.
    Paz-Ares, L. G.
    Robinson, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma
    Feyerabend, S.
    Boegemann, M.
    Goebell, P. J.
    Stoeckle, M.
    Nepert, D.
    Wride, K.
    Thomas, D.
    Loehr, A.
    Simmons, A.
    Grivas, P.
    Chowdhury, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 324
  • [45] First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
    Lakhani, Nehal J.
    Rasco, Drew
    Wang, Hengbang
    Men, Lichuang
    Liang, Eric
    Fu, Tommy
    Collins, Mary C.
    Min, Ping
    Yin, Yan
    Davids, Matthew S.
    Yang, Dajun
    Zhai, Yifan
    CLINICAL CANCER RESEARCH, 2024, 30 (03) : 506 - 521
  • [46] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [47] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [48] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael Sangmin
    Wolf, Ido
    Fakih, Marwan
    De Vos-Geelen, Judith De
    Lee, Valerie
    Vogel, Arndt
    Wu, Larry
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] CLINICAL UPDATE FROM A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL SINGLE AGENT STUDY OF SUPLEXA THERAPEUTIC CELLS IN PATIENTS WITH METASTATIC SOLID TUMOURS AND HAEMATOLOGIC MALIGNANCIES
    Joshi, Rohit
    Goh, Jeffrey
    Joubert, Warren
    Kwarta, Vineet
    Okera, Meena
    Bishnoi, Sarwan
    Lederer, Jim
    Borriello, Frank
    Gargosky, Sharron
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A663 - A663
  • [50] An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors
    Di Paola, Eugenio Donato
    Alonso, Silvia
    Giuliani, Rosa
    Calabro, Fabio
    DAlessio, Antonietta
    Regine, Giovanni
    Cerbone, Linda
    Bianchi, Laura
    Mancuso, Andrea
    Sperka, Sabine
    Rozencweig, Marcel
    Sternberg, Cora N.
    FRONTIERS IN ONCOLOGY, 2012, 2
12345